1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Poulsen, S.-A.
Watson, A.A.
Craik, D.J.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
J.Struct.Biol.
JSBIEM
0803
1047-8477
130
142
152
10.1006/jsbi.2000.4267
10940222
Solution structures in aqueous SDS micelles of two amyloid beta peptides of A beta(1-28) mutated at the alpha-secretase cleavage site (K16E, K16F)
2000
10.2210/pdb1bjc/pdb
pdb_00001bjc
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
3286.500
AMYLOID BETA-PEPTIDE
ABETA [F16], RESIDUES 1-28
K16F
1
man
polymer
no
no
DAEFRHDSGYEVHHQFLVFFAEDVGSNK
DAEFRHDSGYEVHHQFLVFFAEDVGSNK
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
human
Homo
sample
9606
Homo sapiens
32644
unidentified
database_2
pdbx_database_status
pdbx_struct_assembly
pdbx_struct_oper_list
struct_ref_seq_dif
repository
Initial release
Version format compliance
Version format compliance
Database references
Derived calculations
Other
1
0
1998-11-18
1
1
2008-03-24
1
2
2011-07-13
1
3
2021-11-03
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_database_status.process_site
_struct_ref_seq_dif.details
Y
BNL
1998-06-23
REL
REL
THE STRUCTURE WAS DETERMINED FROM 2-DIMENSIONAL NMR DATA ON UNLABELLED PEPTIDE
LOW ENERGY, LOW VIOLATIONS
50
15
NOESY
TOCSY
5.8
1
atm
296
K
REFINEMENT DETAILS CAN BE FOUND IN JOURNAL CITATION ABOVE
SIMULATED ANNEALING USING NOE DISTANCE CONSTRAINTS
SDS MICELLES (100MM)/D2O, H2O
BRUNGER
refinement
XPLOR
structure solution
X-PLOR
500
Bruker
AMX-500
750
Bruker
DRX-750
ASP
1
n
1
ASP
1
A
ALA
2
n
2
ALA
2
A
GLU
3
n
3
GLU
3
A
PHE
4
n
4
PHE
4
A
ARG
5
n
5
ARG
5
A
HIS
6
n
6
HIS
6
A
ASP
7
n
7
ASP
7
A
SER
8
n
8
SER
8
A
GLY
9
n
9
GLY
9
A
TYR
10
n
10
TYR
10
A
GLU
11
n
11
GLU
11
A
VAL
12
n
12
VAL
12
A
HIS
13
n
13
HIS
13
A
HIS
14
n
14
HIS
14
A
GLN
15
n
15
GLN
15
A
PHE
16
n
16
PHE
16
A
LEU
17
n
17
LEU
17
A
VAL
18
n
18
VAL
18
A
PHE
19
n
19
PHE
19
A
PHE
20
n
20
PHE
20
A
ALA
21
n
21
ALA
21
A
GLU
22
n
22
GLU
22
A
ASP
23
n
23
ASP
23
A
VAL
24
n
24
VAL
24
A
GLY
25
n
25
GLY
25
A
SER
26
n
26
SER
26
A
ASN
27
n
27
ASN
27
A
LYS
28
n
28
LYS
28
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
identity operation
0.0000000000
0.0000000000
0.0000000000
1
A
ALA
2
60.07
60.70
1
A
GLU
3
-81.31
35.88
1
A
PHE
4
-154.98
13.12
1
A
ARG
5
-68.31
71.95
1
A
HIS
6
-177.47
-21.00
1
A
GLU
11
-172.26
104.69
1
A
PHE
16
-132.86
-50.39
1
A
SER
26
-88.06
32.77
2
A
GLU
3
-96.51
32.60
2
A
PHE
4
-152.02
62.91
2
A
ARG
5
-164.08
33.16
2
A
HIS
6
51.16
17.43
2
A
SER
8
55.82
17.06
2
A
TYR
10
-65.62
-175.12
2
A
GLU
11
-174.00
113.13
2
A
HIS
13
67.86
-18.56
3
A
GLU
3
-165.83
26.40
3
A
PHE
4
-81.79
34.46
3
A
HIS
6
51.26
11.97
3
A
TYR
10
-70.71
-165.13
3
A
GLU
11
-172.47
115.58
3
A
HIS
13
-178.15
-51.64
3
A
ALA
21
-55.98
-7.71
3
A
ASP
23
-142.03
-34.76
3
A
SER
26
56.54
14.15
4
A
ARG
5
-101.34
49.56
4
A
GLU
11
-171.33
100.17
4
A
HIS
13
44.10
26.78
4
A
HIS
14
36.89
42.54
4
A
GLN
15
-69.74
13.45
4
A
ASP
23
-145.07
32.67
4
A
VAL
24
-136.30
-32.85
4
A
SER
26
-167.18
-42.32
5
A
PHE
4
-107.02
62.14
5
A
ARG
5
-150.52
45.75
5
A
GLU
11
173.82
122.50
5
A
HIS
13
-169.26
-2.37
5
A
GLN
15
-160.15
8.33
5
A
SER
26
-163.79
-39.70
5
A
ASN
27
-87.90
43.79
6
A
ALA
2
-153.37
70.31
6
A
PHE
4
-148.66
29.09
6
A
HIS
6
73.73
51.84
6
A
GLU
11
-170.37
104.84
6
A
HIS
13
-179.33
-59.34
6
A
HIS
14
-170.47
-111.49
6
A
LEU
17
86.00
-27.67
6
A
GLU
22
-141.83
-43.34
7
A
ALA
2
-77.64
-166.46
7
A
GLU
11
-172.17
103.56
7
A
GLN
15
-163.02
26.76
7
A
ALA
21
-66.58
13.02
7
A
ASP
23
-131.70
-37.24
7
A
SER
26
-155.01
70.81
7
A
ASN
27
-141.67
-2.49
8
A
ALA
2
56.04
72.53
8
A
GLU
3
-85.40
45.58
8
A
PHE
4
-165.75
18.33
8
A
HIS
6
65.96
76.07
8
A
ASP
7
-82.81
30.55
8
A
GLU
11
-163.75
106.85
8
A
HIS
13
-174.24
-22.36
8
A
ASP
23
-148.79
30.71
8
A
VAL
24
-132.27
-31.41
9
A
HIS
6
-165.15
-64.53
9
A
TYR
10
61.94
157.74
9
A
GLU
11
-176.84
127.82
9
A
VAL
12
-131.04
-34.10
9
A
HIS
13
77.95
-53.75
9
A
GLN
15
-166.48
51.57
9
A
PHE
16
-133.35
-55.04
10
A
ARG
5
45.22
24.18
10
A
HIS
6
-173.72
9.30
10
A
SER
8
44.60
20.03
10
A
GLU
11
-175.25
127.04
10
A
VAL
12
-97.11
-64.60
10
A
HIS
13
54.64
6.35
10
A
HIS
14
-78.04
-83.20
10
A
VAL
24
-123.44
-51.40
10
A
ASN
27
58.30
6.34
11
A
GLU
3
-78.72
23.00
11
A
PHE
4
-143.21
20.88
11
A
GLU
11
-164.63
103.28
11
A
HIS
13
78.34
-51.16
11
A
HIS
14
-82.92
-153.39
11
A
LEU
17
86.62
-27.99
11
A
ASN
27
-138.85
-32.34
12
A
ALA
2
-105.99
57.18
12
A
ARG
5
-166.57
6.32
12
A
ASP
7
-155.60
23.78
12
A
TYR
10
39.08
-149.14
12
A
HIS
13
78.51
-33.60
12
A
GLN
15
-77.00
33.85
12
A
VAL
24
-131.79
-44.20
12
A
SER
26
-157.13
-33.68
12
A
ASN
27
-140.88
41.36
13
A
ALA
2
-160.35
52.84
13
A
GLU
3
-88.38
34.76
13
A
GLU
11
-174.43
112.74
13
A
HIS
13
69.39
-2.29
13
A
HIS
14
26.08
69.71
13
A
ASP
23
-145.48
27.80
13
A
SER
26
-163.97
69.27
14
A
ALA
2
51.00
74.03
14
A
ARG
5
-157.21
25.18
14
A
HIS
6
-133.81
-50.35
14
A
TYR
10
179.28
166.05
14
A
VAL
12
-121.89
-58.01
14
A
HIS
13
75.13
-49.84
14
A
PHE
19
-65.19
2.72
14
A
ALA
21
-147.32
-33.42
14
A
SER
26
59.13
14.52
15
A
ALA
2
-167.24
69.25
15
A
GLU
3
-82.64
31.48
15
A
ARG
5
-153.13
22.25
15
A
HIS
6
-178.32
-47.40
15
A
TYR
10
48.06
-173.00
15
A
GLU
11
-158.41
83.43
15
A
GLN
15
49.47
24.24
15
A
VAL
24
-139.65
-33.17
15
A
SER
26
-150.97
7.68
model building
X-PLOR
refinement
X-PLOR
phasing
X-PLOR
SOLUTION NMR STRUCTURE OF AMYLOID BETA[F16], RESIDUES 1-28, 15 STRUCTURES
1
Y
N
A
LEU
17
A
LEU
17
HELX_P
A
VAL
24
A
VAL
24
1
1
8
GLYCOPROTEIN
GLYCOPROTEIN, AMYLOID BETA-PEPTIDE, ALZHEIMER'S DISEASE
A4_HUMAN
UNP
1
1
P05067
MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGRLNMHMNVQNGKWDSDPSGTKTCIDTKEGILQYCQEVYPEL
QITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVGEFVSDALLVPDKCKFLHQERMDVCETHLHWHTVAKETCSE
KSTNLHDYGMLLPCGIDKFRGVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTDYADGSEDKVVEVAEEEEVAEVEEE
EADDDEDDEDGDEVEEEAEEPYEEATERTTSIATTTTTTTESVEEVVREVCSEQAETGPCRAMISRWYFDVTEGKCAPFF
YGGCGGNRNNFDTEEYCMAVCGSAMSQSLLKTTQEPLARDPVKLPTTAASTPDAVDKYLETPGDENEHAHFQKAKERLEA
KHRERMSQVMREWEEAERQAKNLPKADKKAVIQHFQEKVESLEQEAANERQQLVETHMARVEAMLNDRRRLALENYITAL
QAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQVMTHLRVIYERMNQSLSLLYNVPAVAEEIQD
EVDELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTETKTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPV
DARPAADRGLTTRPGSGLTNIKTEEISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITL
VMLKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN
672
699
1BJC
1
28
P05067
A
1
1
28
1
LYS
engineered mutation
PHE
16
1BJC
A
P05067
UNP
687
16
1
P 1